Stories

Fighter. Hero. Cancer-stricken. The words and metaphors people use to talk about cancer often feel worlds apart from any other disease. But how far does it go? Do words matter?

What happens when a patient’s only treatment hope rests with a promising but not yet locally approved therapy? At Novartis, we are providing a lifeline of access to innovative medicines under review or not yet approved locally when no other treatment options are available.

When Carl was diagnosed with metastatic prostate cancer, he and his wife Arlene began navigating his cancer journey while still looking to enjoy their retirement – hoping to remain active with family and friends in their retirement community.

Leanne Pero discusses her experiences of life before, during and after breast cancer, and how it inspired her to advocate for herself and others like her.

Thierry Diagana and Jonathan Spector from the Novartis Institute for Tropical Diseases (NITD) discuss learnings about their work in Neglected Tropical Diseases (NTDs) and share insights into the factors, which could lead to a resurgence of these diseases.

Sickle cell disease disproportionately affects babies in Africa, but many go undiagnosed due to lack of screening. Newborn screening is needed to save lives and improve care.

Raising awareness of the ways in which prostate cancer can affect the sexual minority and gender minority communities.

Inspired by Emily Whitehead, along with other early patients treated with CAR-T cell therapy, Novartis embarked on a pioneering journey to reimagine cancer treatment. After 10 years, we continue to relentlessly pursue new science around cell and gene therapies to transform the lives of patients today and in the future.

Low- and middle-income countries will account for some three in four of the world’s cancer deaths within the next decade without better access to care. It’s a gap Amy Israel and her team at Novartis are trying to bridge.